Cover Image
市場調查報告書

Tralokinumab(氣喘治療藥):市場預測與分析

Tralokinumab (Asthma) - Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 316089
出版日期 內容資訊 英文 67 Pages
訂單完成後即時交付
價格
Back to Top
Tralokinumab(氣喘治療藥):市場預測與分析 Tralokinumab (Asthma) - Forecast and Market Analysis to 2023
出版日期: 2014年08月31日 內容資訊: 英文 67 Pages
簡介

Tralokinumab是由AstraZeneca所開發,現在位於臨床實驗第二階段的醫藥品,是針對嚴重、難治性,不可能以標準治療法來控制的氣喘──第三選擇療法(ICS/LABA的大量·配合給藥等)也無法治療的氣喘──為對象所開發的。Tralokinumab是IgG4人體化單株抗體的一種,對IL-13(Th2細胞反應的嗜酸性粒細胞因子)具有抗性。干擾素(interferon)-13(IL-13)正漸漸成為氣喘治療藥新的開發策略目標。這是由於IL-13和IL-4一樣,都與氣管發炎與remodeling(包含產生黏液)、IgE合成、嗜酸性粒細胞·嗜鹼性粒細胞的遞增,更與纖維芽細胞·呼吸道平滑肌細胞的增生有關。

本報告提供氣喘的治療藥之一,Tralokinumab(Tralokinumab)的全球市場相關分析,提供氣喘概要和治療方法,競爭的企業、藥品概要,市場競爭概況,彙整Tralokinumab的商品資訊(特色·功效·安全性等),全球主要國家的市場銷售額預測(今後10年份)等調查,並將結果概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因與病情
    • 病因
    • 病理生理學
    • 預後
    • 生活品質(QoL)
  • 症狀

第4章 疾病管理

  • 診斷·治療概要
    • 診斷
    • 治療的指南,臨床診療,有代表性的處方藥
    • 臨床診療

第5章 競爭評估

  • 概要
  • 競爭企業的策略性評估

第6章 未滿足需求與市場機會

  • 概要
  • 為了管理嚴重氣喘的個體化治療
    • 未滿足需求
    • 差距分析
    • 市場機會
  • 改善病人依從性
  • 降低氣喘藥物的治療費用
  • 恰當的診斷兒童氣喘

第7章 開發平台評估

  • 概要
  • 臨床實驗中有前途的醫藥品

第8章 關於Tralokinumab

  • 概要
  • 功效
  • 安全性
  • 給藥·劑型
  • 在臨床方面的潛在性地位
  • 在商業方面的潛在性地位
  • 價格設定和醫療費給付
  • SWOT分析
  • 預測

第9章 附錄

圖表一覽

目錄

GlobalData has released its new PharmaPoint Drug Evaluation report, "Tralokinumab (Asthma) - Forecast and Market Analysis to 2023". The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.

AstraZeneca's tralokinumab is in Phase II of development for severe, persistent, uncontrolled asthma despite standard-of-care therapy and failing third-line treatment, such as a high-dose ICS/LABA combination. Tralokinumab is an IgG4 humanized mAb against IL-13, which is a pleiotropic cytokine of the Th2 cell response. IL-13 is a key target for new anti-asthma therapeutic strategies because of its involvement, together with IL-4, in several aspects of airway inflammation and remodeling, including mucus production, IgE synthesis, recruitment of eosinophils and basophils, as well as proliferation of bronchial fibroblasts and airway smooth muscle cells.

Scope

  • Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Tralokinumab including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Tralokinumab for the top eight countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Asthma
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Tralokinumab performance
  • Obtain sales forecast for Tralokinumab from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
    • 3.1.4. Quality of Life
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines, Clinical Practice, and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Personalized Therapies to Control Severe Asthma
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Better Patient Compliance
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Lower Cost of Asthma Medications
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Proper Diagnosis of Asthma in Children
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development

8. Tralokinumab

  • 8.1. Overview
  • 8.2. Efficacy
  • 8.3. Safety
  • 8.4. Dosing and Formulation
  • 8.5. Potential Clinical Positioning
  • 8.6. Potential Commercial Positioning
  • 8.7. Pricing and Reimbursement

    8.8. SWOT Analysis

  • 8.9. Forecast

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed Asthma Patients
    • 9.4.2. Percent Drug-Treated Patients
    • 9.4.3. General Pricing Assumptions
    • 9.4.4. Generic Erosion
    • 9.4.5. Pricing of Pipeline Agents
  • 9.5. Physicians and Specialists Included in This Study
  • 9.6. About the Authors
    • 9.6.1. Author
    • 9.6.2. Author/Reviewer
    • 9.6.3. Reviewer
    • 9.6.4. Global Head of Healthcare
  • 9.7. About GlobalData
  • 9.8. Disclaimer

List of Tables

  • Table 1: Symptoms of Asthma
  • Table 2: Treatment Guidelines for Asthma by Country
  • Table 3: Most Prescribed Drugs for Asthma by Class and Disease Severity in the Global Markets, 2013
  • Table 4: Dosing of Common ICSs for Adult Asthma Therapy to Achieve Equivalent Therapeutic Potency
  • Table 5: Recommended Low Daily Dose of ICSs in Children with Asthma Under Five Years of Age
  • Table 6: Leading Treatments for Asthma, 2014
  • Table 7: Unmet Need and Opportunity in Asthma
  • Table 8: Asthma - Late Stage Pipeline, 2014
  • Table 9: Product Profile - Tralokinumab
  • Table 10: Efficacy of Tralokinumab Versus Placebo
  • Table 11: Tralokinumab's Safety Profile
  • Table 12: Tralokinumab SWOT Analysis, 2014
  • Table 13: Global Sales Forecast ($) for Tralokinumab, 2013-2023
  • Table 14: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1:Stepwise Disease Management Approach for Asthma in Adults
  • Figure 2: Stepwise Disease Management Approach for Asthma in Children Age Five and Younger
  • Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in Asthma, 2013-2023
Back to Top